Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07281768 · ClinicalTrials.gov registry record · Phase 2
Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT07281768 is a Phase 2 study that is actively recruiting participants, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 66 participants.
The verdict
NCT07281768, a Phase 2 study, is actively recruiting participants, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and clinical activity of combining cemiplimab, cemiplimab/fianlimab, or cemiplimab/REGN7075 with capecitabine/oxaliplatin (CAPOX) for the neoadjuvant treatment of patients with microsatellite stable (MSS) locally advanced rectal cancer (T2 node-positive, T3 node-negative, T3 node-positive).
Interventions
- DRUG Cemiplimab
- DRUG Capecitabine
- DRUG Oxaliplatin
- DRUG REGN7075
- DRUG Fianlimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2026-07 |
| Est. Completion | 2030-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07281768
The ClinicalTrials.gov registry entry for NCT07281768 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cemiplimab is the first listed.
NCT07281768 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07281768 about?
NCT07281768 is a clinical study titled "Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer". The purpose of this study is to evaluate the safety and clinical activity of combining cemiplimab, cemiplimab/fianlimab, or cemiplimab/REGN7075 with capecitabine/oxaliplatin (CAPOX) for the neoadjuvant treatment of patients with microsatellite stable (MSS) locally advanced rectal cancer (T2 node-pos...
What is the current status of trial NCT07281768?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2026-07. Estimated completion is 2030-07.
What interventions are being tested in trial NCT07281768?
The interventions under investigation include: Cemiplimab (DRUG), Capecitabine (DRUG), Oxaliplatin (DRUG), REGN7075 (DRUG), Fianlimab (DRUG).
Who is sponsoring clinical trial NCT07281768?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.